TABLE 1
FROM:
Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice
Milla Koistinaho, Tarja M Malm, Mikko I Kettunen, Gundars Goldsteins, Sofie Starckx, Risto A Kauppinen, Ghislain Opdenakker and Jari Koistinaho
BACK TO ARTICLETable 1. Strains, numbers, treatment and usage of experimental animals
| Strain | Number of mice | Treatment | Usage |
|---|---|---|---|
| FVB/N | 8 | Saline | TTC at 24 hours |
| 9 | Minocycline | TTC at 24 hours | |
| Balb/C | 8 | Saline | TTC at 72 hours |
| 9 | Minocycline pretreatment | TTC at 72 hours | |
| 9 | Doxycycline pretreatment | TTC at 72 hours | |
| 8 | Minocycline posttreatment | TTC at 72 hours | |
| 6 | Doxycycline posttreatment | TTC at 72 hours | |
| 7 | Aminoguanidine | TTC at 72 hours | |
| MMP-9 ko1 | 10 | Saline | MRI at 72 hours |
| 13 | Minocycline | MRI at 72 hours | |
| C57Bl/6 (controls) | 8 | Saline | MRI at 72 hours |
| 8 | Minocycline | MRI at 72 hours | |
| MMP-9 ko2 | 5 | Saline | MRI at 72 hours |
| 5 | Minocycline | MRI at 72 hours | |
| C57Bl/6 (controls) | 5 | Saline | MRI at 72 hours |
| 5 | Minocycline | MRI at 72 hours |
ko, knockout; MMP-9, matrix metalloprotease-9 gene; MRI, magnetic resonance imaging; TTC, 2,3,5-triphenyltetrazolium chloride.